North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.510

-3.8%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: andy harrison who wrote (67)	11/8/1996 8:13:00 AM
From: andy harrison	of 82

Call me a liar, but I am going to flog this dead horse one more time. Let me recap... The FDA advisory panel recommended that Cetirva is safe and effective in a 1 through 4 shot regimin of all acellular immunizations.No maker can get approval of 1 through 5 until the children get old enough in Sweden to get the fifth shot and the data is reviewed. (Children need to be six years old plus the time to review the data.) NEXT>> The only immunization shot that the advisory panel had any question about with NVX was the forth shot as a booster after three previous whole cell immunizations as only 42 children had received this innoculation. By the end of November, NVX will have enough data for this shot and to prove that it is safe and effective. FYI>>>> Connaught submitted ZERO information on the use of the 4th and 5th. shots as a booster and still got FDA approval. NEXT>>> Unless Sturza becomes Chairman of the FDA, CDC, or HEALTH CZAR, there is no indication of a change in the USA immunization schedule for DTaP. This is why the advisory panel recommended Connaught for shots 1 through 4; Smithkline 1 through 3 and not on shot four; NVX 1 through 4; and Lederle need more data on 1 through 4. FYI>>> Connaught didnt even test DTaP. All they tested was aP and combined the data from DT. There is no doubt that NVX will get approval for the acellular regimin and in time there will be no children available who have had the whole cell shot. This makes the question of NVX and the 4th booster shot a mute point. We are quite comfortable holding stock in NVX. We are not traders. We rode this horse down to $6/share and didnt sell. If you stand by the powers of your convictions and do your homework and get hold of as many research reports as possible you come to the same conclusion. We read Sturza's newsletter and there is nothing that we feel the "REAL" analysts havent addressed and countered. We have a minimum of 3-5 year time frame on NVX and chances are my 2 month old daughter will inherit my stock. PS>>> In the words of the Temptations.... "You cant hurry Love"... especially with a developmental medical company

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next